

Commemorating 100 Years of Biologic Regulation Regulation of Biologics in The United States: From a Rich Tradition To A Challenging Future

Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Food and Drug Administration

Presentation Overview


- History A Rich Tradition
- History CBER Update
- Current Approach to Regulation
- Challenging Future
- Scientific Research



History of Biological Products Regulation


1798	3			1886	5			1894			
	Marine H Service (Public H Agency	Original	Louis Pasteur (Rabies Vaccine)		Heat-Killed 1888 Vaccine		Roux + Yersin (Diphtheria Toxin)		Public Health Labs Produce Diphtheria Antitoxin		2 Biologics Control Act
	Smallpox Vaccination 1800			Koch Isolated Anthrax Bacillus	Public Ser Lab Of Hyg J. Kinyour 1887		giene	Antitoxins 19		13 Children Died of Tetanus due to Contaminated Diphtheria Antitoxin	
			1878	3			189(0			1000 1900 2002 BOLDORS DOMINGLAST COMMERCIAN d'Biologio Regulation

History of Biological Products Regulation (continued)





History of Biological Products Regulation (continued)



Historical Legacy

- Scientists regulated biologic products and are actively involved developing therapies
- Scientist conducted research on problems related to development, manufacture and testing of biologics
- Scientists conducted studies to assure safety, purity, and potency of biologic products, to improve existing products and develop new products.
- Emphasis on licensing/ inspection of manufacturing facilities
- Adverse public health events precipitate change/ regulation



The Mission of the Center for Biologics Evaluation and Research is to protect and enhance the public health through the regulation of biological products including blood, vaccines, therapeutics and related drugs and devices, according to statutory authorities. The regulation of these products is founded on science and law to ensure their purity, potency, safety, efficacy and availability.



Biological Products Regulated By CBER

Vaccines

Allergenic Extracts

Blood Derivatives

Blood Components

Whole Blood

Devices

Tissues

Monoclonal Antibodies

Biotech Derived Therapeutics

> Somatic Cell & Gene Therapy




Xenotransplantation

Office of Cellular, Tissue, and Gene Therapies (OCTGT)

- Increase in promise of, and resultant regulatory activities in, cellular and tissue-based products, gene therapies, xenotransplantation, unique associated reproduction
- Consolidation of products into one office
 - Increasing complexity of products
 - New scientific advances, unique safety issues
 - Need for creative clinical, regulatory and risk management approaches
 - Need for seamless and transparent coordination and communication




Gene Therapy, Somatic Cell Therapy, Xenotransplantation INDs/IDEs Received FY 1984 - FY 2002



Note: A total of 7 INDs were for Xeno and GT, and are included in the counts for both.




Gene Therapy, Somatic Cell Therapy, and Xenotransplantation IND/IDE Amendments Received FY 1984 - FY 2002




Note: A total of 317Amendments were for INDs that are both Xeno and GT and are included in the counts for both.



Biological – Medical Device Combination Products





SOME PRODUCTS AT CBER TOMORROW

TODAY Monoclonal Antibodies

Therapeutic Vaccines

Therapeutic Vaccines

rDNA Therapeutic Proteins

Blood Derivatives and recombinant analogues

Ancillary products

Blood Derivatives and recombinant analogues


Ancillary products



Current Approach To Regulation



Regulation of FDA Products Based on Sound Science, Law, and Public Health Impact



FDA Policy Development

Legislative Laws

- FDA Regulation public rule making
- FDA Guidance public notice and comment

More focused More specific

- Communicate CBER's current thinking on topic
- Often provides acceptable approaches
- However, alternate and acceptable approaches may also be used
- Option to submit draft guidance to FDA for consideration



Policy Development

- Transparent Process & Opportunity to Comment
- Meetings
 - Public Hearings
 - FDA/ HHS Advisory Committees focus specific products, specific concerns
 - Scientific Meetings/ Workshops specific topic
- Scientific Research
- International component (e.g., ICH, WHO)
- Policy is revised as appropriate

- Regulation and Rules - always open for comment



Product Development and Regulation

- GOAL: Balanced, flexible, responsive regulatory approach
 - Assure the safety and rights of subjects
 - Protect the public health
 - Not impede technological innovation & product development
- Influences
 - Available scientific knowledge, pre-clinical, clinical knowledge & experience
 - Crises/ tragic events
- Timing to develop policy, especially written policy
- Appropriate Risk Assessment



Gene Therapy Experience

- Increase in subject protection
 - Increased transparency on GT clinical studies
 - Investigator disclosure
 - Increased monitoring of clinical trials
- Described in IND "cGMP information"
 - An adequate QA/ QC program for manufacture of clinical gene therapy products
 - Description of segregation and cleaning procedures to prevent cross-contamination from production of multiple GT vectors in the same facility



Cells and Tissues

- Some Human Cells and Tissues and Cellular/ Tissue-Based Products – regulated by a fragmented approach
- Examples
 - musculoskeletal tissue
 - ocular tissue
 - cellular therapies
 - hematopoeitic stem cells
 - reproductive tissue
 - combination tissue/device; tissue/drug
 - human heart valves
 - dura mater



"New" FDA Approach to Regulation of Cells and Tissues - Tissue Rule (February 1997)

<u>Objective</u>

- Provide a unified, comprehensive regulatory framework
- Provide greater flexibility and innovation in this field of medicine
- Increased predictability of regulatory requirements
- Provide a tiered regulatory approach with the level of regulation proportional to the degree of risk

Five Areas of Regulatory Concern

- Preventing transmission of communicable disease
- Safe processing and handling
- Clinical safety and effectiveness, where appropriate
- Promotional claims
- Monitoring of industry



Product Characteristics

- Autologous vs. allogeneic
- Viable vs. nonviable
- Banked vs. unbanked
- Homologous vs. non-homologous function
- Minimal vs. more than minimal manipulation
- Structural vs. systemic function
- Combination tissue/device or tissue/drug



"Banked" Human Cells/Tissues Intended For Transplantation

- Tissue recovered, processed, stored, or distributed by methods not intended to change tissue function or characteristics
- Minimally manipulated, homologous use, metabolic tissue for self or close blood relative, or for reproductive use
 - <u>Examples</u>: bone, muscle, cornea, reproductive tissue, heart valves, dura mater and hematopoietic stem cells – (if minimally manipulated)
- Regulated only under <u>communicable disease</u> provisions of PHS Act ("361 Products")
 - Comply with Tissue Rule (Registration, GTP's, Donor Suitability)
 - Premarket approval not required, no submission



Cells & Tissues Regulated as Biologics or Devices


- The cells or tissues are:
 - Expanded, activated, genetically modified or encapsulated Non-normal/ Non-homologous use (ex: skeletal muscle in heart)
 - Clinical effect is systemic or dependent upon the metabolic activity of the cells for its primary function (e.g., pancreatic islets, hepatocytes, neurons)
 - Combined with another drug, device or biologic
- Regulated under more stringent <u>safety and efficacy</u> provisions of PHS Act (351) and FD&C Act (regulated as Biologic or Device)
 - Comply with Tissue Rule (Registration, GTP's, Donor Suitability)
 - Premarket review required controlled clinical trials needed to demonstrate safety and efficacy.

Standards Development "Leveraging"

- Standards Organizations
 - Non governmental organizations (NGO)
 - Serve as facilitators to develop standards
- Identify Standard to be Developed
 - Participation by interested parties
 - Transparent Process
 - Agreement on "standard" reached by consensus
- Option for FDA to participate in development of standards
- Option for FDA to adopt standards



Adenovirus Vector Reference Material





Development of Adenovirus Vector Reference Material

- Issue Determination of infectious particle/ dose of Adenoviral gene vector
- Workshop participation by interested parties including industry & regulators
- Development of requirements for reference material specified by FDA
- Open Bid for services to develop & test material
- Reference material manufactured and released
- Transparency of process and results
- Reference: www.WilBio.com



Challenges



CBER's Public Health Challenges

- Vaccine Safety and Availability
- Blood Safety and Availability
- Emerging Infectious Diseases
- Gene Therapy
- Xenotransplantation
- Human Tissues and Cell Products
- Counter-Bioterrorism
- New Technologies



Emerging New Technologies- Biomedical Research and Technology

- Proteomics
- Genomics
- Mass Spectroscopy
- Nuclear Magnetic Resonance Spectroscopy
- Plasma Resonance Spectroscopy
- PCR methods, e.g. MAPREC, TAQ-MAN



Application

- Product Quality
 - Complex Biological Product Characterization
 - Release Testing
 - Manufacturing process monitoring
 - Adventitious Agent Detection and Quantitation
 - Transitioning from Animal/Human Testing to Analytical, In Vitro, or Biochemical Testing
- Biological Assessments
 - Mechanisms of Immunity or Immunomodulation
 - Biological Responses
 - Mechanisms of Disease Pathogenesis
 - Mechanisms of Product Toxicity



The Future Challenges of New Technologies


- Quantitation
- Validation
- Robustness
- Standards
- Imagination and creativity in their application



Scientific Research



Shepherding Safe and Effective Products



Functions of CBER Research

- Encourages industry-wide adoption of new technologies
- Facilitates development of industry-wide standards and methods
- Contributes to improving existing products and developing new products
- Aids in recruiting and retaining excellent scientists



Other Approaches To Research "Leveraging"

- Collaborative Research
 - CBER NIH
 - CBER Industry
- Pharmaceutical Quality Research Institute (Traditional Pharmaceuticals)
 - consortium of participants provide funding to research a specific issues
 - typically impacting on a regulatory issue potential for reduction in regulatory burden



CBER Available Documents

On-line

-www.fda.gov/cber/publications.htm

- Outside US: 301-827-3844
- Email -Manufacturers assistance: <u>MATT@CBER.FDA.GOV</u>
- CBER Voice Information System at: – 1-800-835-4709 or 301-827-1800

